The effects of booster vaccination on combined hepatitis A and hepatitis B vaccine in both anti-HBs and anti-HAV negative children 5-15 years after hepatitis B vaccine primary immunization

In the present study, we investigated the changes in both anti-HAV lgG and anti-HBs lgG levels and compared the antibody seroconversion rates of different doses of combined hepatitis A and hepatitis B vaccine in children. Children who were vaccinated as infants with Hepatitis B vaccine were revaccin...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 9; no. 4; pp. 898 - 902
Main Authors Chen, Yongdi, Gu, Hua, Cheng, Suyun, Shen, Lingzhi, Cui, Fujiang, Wang, Fuzhen, Yao, Jun, Xia, Shichang, Lv, Huakun, Liang, Xiaofeng
Format Journal Article
LanguageEnglish
Published United States 01.04.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In the present study, we investigated the changes in both anti-HAV lgG and anti-HBs lgG levels and compared the antibody seroconversion rates of different doses of combined hepatitis A and hepatitis B vaccine in children. Children who were vaccinated as infants with Hepatitis B vaccine were revaccinated at 5-15 y of age, then the antibody titers were monitored. Among 283 children, this study found that the anti-HAV seroconversion rates (defined as anti-HAV ≥ 1 mIU/ml) after the first and the third dose were 79.9% and 100% respectively; these observed differences were statistically significant (P<0.05); the corresponding geometric mean titers (GMTs) were 4.72 ± 2.63 mIU/ml and 13.46 ± 1.16 mIU/ml respectively. The anti-HBs seroconversion rates (defined as an anti-HBs ≥ 10 mIU/ml) were 82.3% and 99.0% respectively; these observed differences were statistically significant (P<0.05); and the corresponding titers were 319.95 ± 5.16 mIU/ml and 418.59 ± 3.89 mIU/ml respectively. After the first booster dose, the difference in anti-HAV seroconversion rate was statistically significant in children aged 5-9 y and 10-15 y (P<0.05), as was the difference of anti-HBs seroconversion, whereas after the third dose the difference was not statistically significant (P>0.05). This study demonstrated that the immunization effects of booster vaccination with combined hepatitis A and hepatitis B vaccine is successful for children. A single booster dose is adequate for younger children, while three doses are needed for older children.
AbstractList In the present study, we investigated the changes in both anti-HAV lgG and anti-HBs lgG levels and compared the antibody seroconversion rates of different doses of combined hepatitis A and hepatitis B vaccine in children. Children who were vaccinated as infants with Hepatitis B vaccine were revaccinated at 5-15 y of age, then the antibody titers were monitored. Among 283 children, this study found that the anti-HAV seroconversion rates (defined as anti-HAV ≥ 1 mIU/ml) after the first and the third dose were 79.9% and 100% respectively; these observed differences were statistically significant (P<0.05); the corresponding geometric mean titers (GMTs) were 4.72 ± 2.63 mIU/ml and 13.46 ± 1.16 mIU/ml respectively. The anti-HBs seroconversion rates (defined as an anti-HBs ≥ 10 mIU/ml) were 82.3% and 99.0% respectively; these observed differences were statistically significant (P<0.05); and the corresponding titers were 319.95 ± 5.16 mIU/ml and 418.59 ± 3.89 mIU/ml respectively. After the first booster dose, the difference in anti-HAV seroconversion rate was statistically significant in children aged 5-9 y and 10-15 y (P<0.05), as was the difference of anti-HBs seroconversion, whereas after the third dose the difference was not statistically significant (P>0.05). This study demonstrated that the immunization effects of booster vaccination with combined hepatitis A and hepatitis B vaccine is successful for children. A single booster dose is adequate for younger children, while three doses are needed for older children.
Author Lv, Huakun
Yao, Jun
Xia, Shichang
Chen, Yongdi
Cheng, Suyun
Liang, Xiaofeng
Wang, Fuzhen
Shen, Lingzhi
Gu, Hua
Cui, Fujiang
Author_xml – sequence: 1
  givenname: Yongdi
  surname: Chen
  fullname: Chen, Yongdi
  organization: Zhejiang Provincial Center for Disease Prevention and Control; Hangzhou, P.R. China
– sequence: 2
  givenname: Hua
  surname: Gu
  fullname: Gu, Hua
– sequence: 3
  givenname: Suyun
  surname: Cheng
  fullname: Cheng, Suyun
– sequence: 4
  givenname: Lingzhi
  surname: Shen
  fullname: Shen, Lingzhi
– sequence: 5
  givenname: Fujiang
  surname: Cui
  fullname: Cui, Fujiang
– sequence: 6
  givenname: Fuzhen
  surname: Wang
  fullname: Wang, Fuzhen
– sequence: 7
  givenname: Jun
  surname: Yao
  fullname: Yao, Jun
– sequence: 8
  givenname: Shichang
  surname: Xia
  fullname: Xia, Shichang
– sequence: 9
  givenname: Huakun
  surname: Lv
  fullname: Lv, Huakun
– sequence: 10
  givenname: Xiaofeng
  surname: Liang
  fullname: Liang, Xiaofeng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23295964$$D View this record in MEDLINE/PubMed
BookMark eNptUE1Lw0AQXUSxtRb8BbJHL6nZj2y6x7aoFQpeqngL2c3ErCSbmE0K9bf541zbCB4cBoaZee_N8C7Qqa0tIHRFwhkngtwWuxllRLITNKZE8CCK-OsITZ17D33EIeVCnKMRZVRGUvAx-toWgCHPQXcO1zlWde06aPEu1drYtDO1xT51XSljIcMFNH7YGYcXOLV_--XAAWysl-kKv-9MsF66A_DYLF6whTfP2AHWhSmzFiyOAhLhPaStR-Y_x_8TbVpTpe0em6rqrfk8fHaJzvK0dDAd6gQ9399tV-tg8_TwuFpsgoYS0gVKUamJpjImoXdlrulca8KEyGIilNSCcJpLJVUm9FxHnMgwBZ2p2M8FyyM2QTdH3aatP3pwXVIZp6EsUwt17xLCOePeXsY89HqA9qqCLBneTn4dZ9_M6oQK
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.4161/hv.23193
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2164-554X
EndPage 902
ExternalDocumentID 23295964
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
0VX
0YH
30N
4.4
53G
AALUX
ABEIZ
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AEXWM
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
CGR
CUY
CVF
DGEBU
DIK
EBS
ECM
EIF
EJD
EMOBN
GROUPED_DOAJ
H13
HYE
IPNFZ
KYCEM
LJTGL
M4Z
NPM
O9-
OK1
OVD
RIG
RPM
SV3
TDBHL
TEORI
TFL
TFW
TTHFI
7X8
ID FETCH-LOGICAL-p211t-bb29c1c297102168c28cc1366d716b9c6142f9b9bd6c8c54190aecdb714263f53
IngestDate Sat Aug 17 02:45:05 EDT 2024
Sat Sep 28 07:52:24 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords anti-HBs
booster vaccination
combined hepatitis A and hepatitis B vaccine
anti-HAV
effect
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p211t-bb29c1c297102168c28cc1366d716b9c6142f9b9bd6c8c54190aecdb714263f53
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
PMID 23295964
PQID 1443400733
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_1443400733
pubmed_primary_23295964
PublicationCentury 2000
PublicationDate 2013-Apr
20130401
PublicationDateYYYYMMDD 2013-04-01
PublicationDate_xml – month: 04
  year: 2013
  text: 2013-Apr
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2013
References 10571600 - Aliment Pharmacol Ther. 1999 Nov;13(11):1445-9
15231119 - Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jun;25(6):470-3
17707557 - Vaccine. 2007 Oct 10;25(41):7160-7
19892043 - Vaccine. 2010 Jan 8;28(3):730-6
1408488 - Pediatr Infect Dis J. 1992 Oct;11(10):866-74
12192159 - Pediatr Infect Dis J. 2002 Aug;21(8):727-30
10547415 - Vaccine. 1999 Nov 12;18(7-8):581-7
11375963 - Gastroenterology. 2001 Jun;120(7):1828-53
19817017 - Wkly Epidemiol Rec. 2009 Oct 1;84(40):405-19
20153793 - Vaccine. 2010 Apr 1;28(16):2860-4
16014593 - JAMA. 2005 Jul 13;294(2):194-201
21989290 - Hum Vaccin. 2011 Oct;7(10):1055-9
15807160 - Przegl Epidemiol. 2004;58 Suppl 1:66-70
15755592 - Vaccine. 2005 Mar 18;23(17-18):2185-9
16162883 - N Engl J Med. 2005 Sep 15;353(11):1124-34
10048681 - Pediatr Infect Dis J. 1999 Feb;18(2):109-14
18377352 - Expert Rev Vaccines. 2007 Dec;6(6):891-902
20077662 - Zhongguo Yi Miao He Mian Yi. 2009 Apr;15(2):152-8
19729084 - Vaccine. 2009 Nov 5;27(47):6550-7
12057615 - Vaccine. 2002 Jun 7;20(19-20):2579-84
19469708 - J Infect Dis. 2009 Jul 1;200(1):39-47
10534356 - Hepatology. 1999 Nov;30(5):1312-7
17920732 - Vaccine. 2007 Nov 19;25(47):8085-90
11027806 - Vaccine. 2000 Oct 15;19(4-5):437-41
18444799 - J Infect Dis. 2008 May 15;197(10):1419-26
References_xml
SSID ssj0000702466
Score 1.9661341
Snippet In the present study, we investigated the changes in both anti-HAV lgG and anti-HBs lgG levels and compared the antibody seroconversion rates of different...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 898
SubjectTerms Adolescent
Child
Child, Preschool
Female
Hepatitis A Antibodies - blood
Hepatitis A Vaccines - administration & dosage
Hepatitis A Vaccines - immunology
Hepatitis B Antibodies - blood
Hepatitis B Vaccines - administration & dosage
Hepatitis B Vaccines - immunology
Humans
Immunization, Secondary - methods
Immunoglobulin G - blood
Male
Time Factors
Vaccines, Combined - administration & dosage
Vaccines, Combined - immunology
Title The effects of booster vaccination on combined hepatitis A and hepatitis B vaccine in both anti-HBs and anti-HAV negative children 5-15 years after hepatitis B vaccine primary immunization
URI https://www.ncbi.nlm.nih.gov/pubmed/23295964
https://search.proquest.com/docview/1443400733
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3datswFBZZx2A3Y_9t1xYNdhfczbIkW5dJaQmjyy6WjOzKWLKT-MYus11IHqpPsIfbkSw7Gs2gGwQTGelAcj4ffUc-Pwh9WIYRZwFLdaHbABwUGnoJqN2ThPhKAAEJqU5w_jLlkzn9vGCLweDOiVpqanmutnvzSv5Hq3AP9KqzZP9Bs71QuAHfQb9wBQ3D9cE6dgIygDDrsgfD20SpvLBc0ISZg_sLxHKd6fDpOq_AGujz8t14bNeYCiKyNOlude5NxpUt5qoHo-_DIlu1hcL7HHDm-Wy4gcelsu3G9wm9sSUtcpOMst2BwbLi9k2CnV0ZNJqpbnZYz_0vbD7Jj7JYpXkfP9SYTbRJ3GntSXizafon4JtdDC74arvO3TMP3X-iD5XJjG0k4OV5wIQWriEXDl6pY5Sjts-13d-FyfC-t3VoRw_0vb49B8bbNm38szr39Gt8Nb--jmeXi9kj9JiEgukQ0uDTtD_TA_NJKOdtjWMt8GMn7u_-i-Exs-fomXVA8KhF0ws0yIqX6EnbknTzCv0CTGGLKVwuscUUdjCF4dNhCvfqxiMMUHHGY7smw3mBNaZwhykzscMU7jCFO0xhjSlsMIUNpvYKtZjCLqZeo_nV5exi4tkOH94N8f3ak5II5SsiNM_1eaRIpJQfcJ6CGy-FAu5IlkIKmXIVKUaBvSaZSmXo6z4DSxa8QQdFWWSHCDPw2wP4e1KaUMpoGiWSC5EKwpNU0_wj9L7TQAwWVL8WS4qsbCpwfmlATfPSI_S2VU1sf0MM_oYAyfT4Aavfoac7rJ6gg_pnk50CY63lmYHJb_4OoAg
link.rule.ids 315,786,790,27955,27956
linkProvider Taylor & Francis
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+booster+vaccination+on+combined+hepatitis+A+and+hepatitis+B+vaccine+in+both+anti-HBs+and+anti-HAV+negative+children+5-15+years+after+hepatitis+B+vaccine+primary+immunization&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Chen%2C+Yongdi&rft.au=Gu%2C+Hua&rft.au=Cheng%2C+Suyun&rft.au=Shen%2C+Lingzhi&rft.date=2013-04-01&rft.eissn=2164-554X&rft.volume=9&rft.issue=4&rft.spage=898&rft.epage=902&rft_id=info:doi/10.4161%2Fhv.23193&rft.externalDBID=NO_FULL_TEXT